Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.

MLA

Matsuyama, Yasushi, et al. “Proteasomal Non-Catalytic Subunit PSMD2 as a Potential Therapeutic Target in Association with Various Clinicopathologic Features in Lung Adenocarcinomas.” Molecular Carcinogenesis, vol. 50, no. 4, Apr. 2011, pp. 301–09. EBSCOhost, https://doi.org/10.1002/mc.20632.

APA

Matsuyama, Y., Suzuki, M., Arima, C., Huang, Q. M., Tomida, S., Takeuchi, T., Sugiyama, R., Itoh, Y., Yatabe, Y., Goto, H., & Takahashi, T. (2011). Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Molecular Carcinogenesis, 50(4), 301–309. https://doi.org/10.1002/mc.20632

Chicago

Matsuyama, Yasushi, Motoshi Suzuki, Chinatsu Arima, Qin Miao Huang, Shuta Tomida, Toshiyuki Takeuchi, Ryoji Sugiyama, et al. 2011. “Proteasomal Non-Catalytic Subunit PSMD2 as a Potential Therapeutic Target in Association with Various Clinicopathologic Features in Lung Adenocarcinomas.” Molecular Carcinogenesis 50 (4): 301–9. doi:10.1002/mc.20632.